Stereotactic body radiotherapy (SBRT) in combination with drugs in metastatic kidney cancer: A systematic review.
Immunotherapy
Renal cancer
Stereotactic radiotherapy
Target therapy
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
15
11
2020
revised:
15
01
2021
accepted:
20
01
2021
pubmed:
6
2
2021
medline:
9
3
2021
entrez:
5
2
2021
Statut:
ppublish
Résumé
To conduct a systematic review and meta-analysis of the role of SBRTdrug combination in patients affected by mRCC and associated oncologic outcomes and toxicity profiles. We performed a critical review of the Pubmed, Medline, and Embase databases from January 1, 2000 through April 30, 2020 according to the Preferred Reporting Items and Meta-Analyses statement. To assess the overall quality of the literature reviewed, we used a modified Delphi tool. A total of 6 studies were included, corresponding to a cohort of 216 patients. Tyrosine Kinases Inhibitors were the most widely used drugs in combination with SBRT, being administered in 93% patients. No study reported an increase of radiation-induced toxicity. SBRT resulted to be safe, without increase in terms of drugs-related adverse events in this setting. Moreover, this approach showed promising clinical outcomes in terms of LC and OS.
Identifiants
pubmed: 33545356
pii: S1040-8428(21)00030-5
doi: 10.1016/j.critrevonc.2021.103242
pii:
doi:
Substances chimiques
Pharmaceutical Preparations
0
Types de publication
Journal Article
Meta-Analysis
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103242Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.